News

February 4, 2021

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

February 3, 2021

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

January 26, 2021

Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities

January 19, 2021

Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts

January 5, 2021

Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M

December 22, 2020

Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

December 11, 2020

Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors

November 27, 2020

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency

November 4, 2020

Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020

November 2, 2020

Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results